A Double-Blind, Placebo-Controlled Study With 2-Docosahexaenoyl-3-Phosphatidylserine in Cognitive Disorder

INTERVENTION: 2‐Docosahexaenoyl‐3‐Phosphatidylserine 100 mg/day (9 capsules/day) for 12 weeks 2‐Docosahexaenoyl‐3‐Phosphatidylserine 300 mg/day (9 capsules/day) for 12 weeks Placebo (9 capsules/day) for 12 weeks CONDITION: Cognitive Disorder PRIMARY OUTCOME: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [Time Frame: 0, 12 weeks] SECONDARY OUTCOME: Profile of Mood States (POMS) [Time Frame: 0, 6,12 weeks]; Japanese Adult Reading Test (JART) [Time Frame: 0 week]; Brain CT or MRI [Time Frame: 0 week]; Serum Brain‐Derived Neurotrophic Factor(BDNF) [Time Frame: 0, 12 weeks]; Food frequency questionnaire [Time Frame: 0 week] INCLUSION CRITERIA: 1. Those who are 55 years old or older without any physical impairment in daily life. 2. Those who have subjective memory impairment 3. Those aged between 55 and 59 whose total scores of RBANS are 220 or under, those aged between 60 and 69 whose scores are 200 or under, and those aged 70 or over whose scores are 180 or under.